Forecast

There is no analyst data available for this company.

News Go to news feed

Cue Biopharma receives about $30 million financing after Q1 loss

Cue Biopharma reported a net loss of $5.2 million in Q1 2026 versus $12.3 million a year earlier, increased revenue to $5.7 million thanks to a collaboration with Boehringer Ingelheim, and cut R&D spending to $6.9 million. As of March 31 the company had $16.4 million in cash; after quarter-end it completed a private placement that raised about $30 million and also received a $7.5 million milestone payment. Cue plans IND filings for CUE-221 (expansion to food allergies) and CUE-401 (autoimmune diseases) in the second half of 2026 and appointed Dr. Shao-Lee Lin as president and CEO. » More on de.investing.com
Cue Biopharma implements 1-for-30 reverse stock split to meet Nasdaq minimum requirement

Cue Biopharma will implement a 1-for-30 reverse split effective Thursday at 5:00 p.m. ET; every 30 existing common shares will be combined into one new share and fractional shares will be paid in cash. Outstanding options and warrants and shares available under option plans will be adjusted proportionally, and trading on a split-adjusted basis is expected to begin Friday under the ticker CUE. The move is intended to satisfy the minimum bid requirement for listing on the Nasdaq Capital Market; the company also received a $7.5 million milestone payment from Boehringer Ingelheim and appointed Lucinda Warren as interim president and CEO. » More on de.investing.com
Cue Biopharma puts T-cell modulation and partnerships at the center

At the Cantor Global Healthcare Conference, Cue Biopharma presented its strategic focus on T-cell modulation and reported pipeline progress, including CUE-401 for autoimmune diseases and the partner-developed CUE-501 with Boehringer Ingelheim. The company ended the quarter with $28 million in cash and an annual burn rate of about $25–28 million; additional funding is expected to come from partnerships and milestone payments. CUE-101 showed significant survival benefits in oncology studies both alone and in combination with Keytruda, and a positive pre‑IND meeting with the FDA paves the way for an IND submission for CUE-401 in June 2026. Several preclinical milestones for CUE-401 and CUE-501 are expected over the next 12–18 months. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, Cue Energy Resources Aktie has already paid €0.00149 in dividends. The last payout was in March.

Financials

In the last quarter, Cue Energy Resources Aktie had revenue of €14.86M and net profit of -€454.83K

(EUR)	June 2026	YoY
Revenue	14.86M	-
Gross profit	5M	-
Net profit	-454.83K	-
EBITDA	4.79M	-

Fundamentals

Metric	Value
Market capitalization	€49.93M
Number of shares	703.17M
52-week high/low	€0.0957 - €0.0605
Dividend yield	5.80%
Dividends TTM	€0.0043
Beta	-0.06
P/E ratio	18.55
PEG ratio	-0.60
P/B ratio	1.42
P/S ratio	1.61

Company profile

Cue Energy Resources Limited ist ein Erdöl- und Erdgasexplorations- und -produktionsunternehmen, das Erdöl exploriert, entwickelt und produziert. Das Unternehmen besitzt Erdölvorkommen in Australien, Neuseeland und Indonesien. Das Unternehmen wurde 1981 gegründet und hat seinen Hauptsitz in Melbourne, Australien.